Vemurafenib as first line therapy in BRAF-mutated Langerhans cell histiocytosis
Author:
Publisher
Elsevier BV
Subject
Dermatology
Reference3 articles.
1. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation;Haroche;Blood,2013
2. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAFV600E mutated Erdheim-Chester disease;Haroche;J Clin Oncol,2015
3. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma;Ascierto;J Clin Oncol,2013
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. From mutation to management: Advancing Langerhans cell histiocytosis treatment through combination therapies;British Journal of Haematology;2024-04-12
2. Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E–positive LCH;Blood Advances;2023-09-13
3. Cutaneous Disorders of the External Ear;Atlas of Dermatology, Dermatopathology and Venereology;2021-10-31
4. Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA;International Journal of Hematology;2021-08-12
5. Neuroendocrine manifestations of Langerhans cell histiocytosis;The Human Hypothalamus - Neuroendocrine Disorders;2021
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3